Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

May 13, 2025

OTC Pink Market US Health Care Biotechnology earnings 53 min

Earnings Call Speaker Segments

Ed Berg

executive
#1

Good afternoon, everyone, and thank you for joining today's call. With us from Vaxart are Steven Lo, our Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phillip Lee, Chief Financial Officer. Before we get started, I want to remind all of you that on this conference call, Vaxart might make forward-looking statements, including statements regarding the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Actual results could differ materially from those discussed in these forward-looking statements because of a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the risk factors section of Vaxart's most recently filed annual report on Form 10-K, and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call. I'll now turn the call over to Steven Lo. Steve?

Steven Lo

executive
#2

Thank you, Ed, and I appreciate everyone being here this afternoon. To kick off today's call, I want to recognize the folks at BARDA alongside the Department of Health and Human Services, and express our gratitude for the constructive back-and-forth we've had with them. That dialogue resulted in the stop work order being lifted for the 10,000 participant portion of our Project NextGen Phase 2b COVID-19 vaccine trial. Our sense is that the extra examination and scrutiny applied to the trial design, along with the data backing the safety and efficacy of our COVID-19 oral pill vaccine program, will in the end inspire more confidence in what the study shows. We realize some of you have felt frustrated that we weren't giving real-time updates about our ongoing talks with BARDA and HHS, and we've fielded numerous questions during this stretch about why we weren't communicating with shareholders. We absolutely understand how important timely and transparent communication is to you, yet contractual obligations with BARDA and HHS, plus the confidential character of these discussions, restrict what we can disclose. Sticking to those obligations matters greatly for the productive relationships we've built with both agencies and, as I hope you'll see, has been vital for the continued advancement of our COVID-19 program. In balancing the constraints of our Project NextGen contractor obligations with our SEC reporting requirements, we will keep disclosing material information promptly through our filings on Form 8-K, and wherever we obtain the necessary and timely approvals, we will also put out press releases. James will soon give an update on where the Phase 2b COVID-19 study stands and what steps we're taking to get patient dosing started. The key point, though, is that we're thrilled to be actively screening patients and hopeful that dosing will begin in the 10,000 participant portion of the study during the second quarter of 2025. Let me also mention that we're operating under our existing contract with BARDA, which remains unchanged and still offers up to $460.7 million for the Phase 2b study. James will likewise update you on our norovirus vaccine clinical program, but I want to point out that we're pleased to have wrapped up enrollment quickly in our Phase 1 trial comparing our second generation constructs against our first generation constructs. Even though this trial is open label, we remain blinded to all study results right now. We anticipate reporting top-line data from this trial in mid-2025, consistent with the guidance we've previously stated. We're still having meaningful conversations with potential strategic partners who are watching this upcoming data readout closely. Should the data confirm our research thesis of an improved norovirus second-generation construct, our belief is that it could result in a partnership that would push the program further forward and might bring additional non-dilutive funding to the company. If we zoom out for a moment, our view is that vaccines form a cornerstone of the public health framework; by numerous measures, they rank among the greatest public health breakthroughs of the 20th century. Substantial economic advantages exist as well, including reduced expenses for our healthcare system and gains in workplace productivity overall. When you set a vaccine against pharmaceutical products, a vaccine is able to reach a stable revenue plateau at its peak, while a pharmaceutical may decline sooner within its product lifecycle. The journey of launching a new vaccine is long and requires significant capital; and as we keep confronting the challenges present in the biotech landscape, we were forced to make certain hard decisions so that we could reach our forthcoming milestones while staying within our current cash resources; this involves cutting our costs via an additional wave of staff reductions over the last few weeks; we take no pleasure in doing this, yet it is regrettably required for us to trim our expenses so we can make the most of our future opportunities. Lastly, as was stated in a press release that went out earlier today, Phil Lee has tendered his resignation from the CFO role for personal reasons. I want to express my gratitude to Phil for the meaningful contributions he delivered throughout his time at Vaxart; we truly value his readiness to remain as a non-executive employee for several weeks so that a seamless transition can occur for the CFO joining us, Jeroen Grasman. We could not be more thrilled that Jeroen has come aboard at Vaxart. A veteran executive in healthcare and finance, Jeroen carries over 20 years of experience in biotech, with his four most recent years spent at AltruBio, a clinical stage private biotech company. In that role he was key in guiding finance and operations and assisted in scaling the company for global clinical studies. Jeroen also enjoyed successful stints at PACT Pharma, Intarcia Therapeutics, and Genentech. We are eager to collaborate with Jeroen and extend him a warm welcome to our team. I will now hand the call over to James for a review of our COVID-19 and norovirus clinical programs. James?

James Cummings

executive
#3

Appreciate that, Steve. To begin, I want to echo Steve in thanking our government partners for their teamwork and backing, which made it possible for the stop work order to be removed from the 10,000 participant portion of the COVID-19 Phase 2b clinical trial. After the April 24th notification arrived that the hold had been released, we returned to the tasks required to begin dosing in this section of the study — reactivating clinical trial sites, evaluating individuals for the study, and coordinating delivery of clinical trial materials. To give a quick summary, the 10,000-person section of this study is meant to measure how our KP2 oral vaccine candidate performs versus an mRNA comparator targeting KP2, looking at efficacy, immunogenicity, and safety. Everyone enrolled is tracked across a 12-month period so we can evaluate the safety, efficacy, and immunogenicity of our oral pill COVID-19 vaccine candidate. We'll determine efficacy among subjects regardless of whether they show COVID-19 symptoms. As for the study's 400-participant sentinel cohort, our per-protocol follow-up work has continued. Within that cohort, the comparison is between our oral pill XBB candidate and an mRNA XBB comparator, not KP2. The sentinel group was set up mainly to gather safety data about our new vaccine construct. Even so, we're excited about the early safety, immunogenicity, and efficacy findings it should give us. The threat COVID-19 poses to human health hasn't gone away. Our oral pill vaccine candidate, in our view, may achieve stronger efficacy than shots. The reason is that it generates mucosal immunity at the very spot where the virus enters the body. Beyond that, for those who dislike needles, a swallowable vaccine is a valuable alternative. I'll now turn to the clinical program for our norovirus vaccine. During the previous month, we shared that all sixty individuals had been enrolled in an open label Phase 1 study testing various doses, and this was accomplished quickly. The design of this trial allows for a head-to-head comparison between our second generation oral norovirus vaccine candidate and the first generation version. This study aims to assess safety and measure immune markers associated with protection, drawing on data from the challenge trial we previously completed with our original norovirus vaccine candidate. We continue to anticipate top line results near the midpoint of 2025. A lot of you are probably asking why, rather than just continuing ahead with our first-generation norovirus vaccine construct, we made the decision to go back to Phase 1 development using a second-generation norovirus vaccine candidate. The short answer is this: our organization is centered on vaccines that come out of data, and our mission is to build oral pill vaccines that lead their class, provide the strongest and most durable protection against infection and disease symptoms, and carry the best odds of commercial success. That's why we carefully go through the results of each preclinical and clinical study, and then use those data to improve our vaccine candidates. Drawing on insights gained from our initial norovirus vaccine candidate — including the finished challenge study as well as the trial we ran in older adults — plus preclinical data from our next-generation norovirus vaccine candidate, we expect this newer candidate may deliver improved defense against infection and illness caused by norovirus. After consulting our advisors and regulators, pursuing this path lets us advance our norovirus vaccine clinical program using the strongest candidate available. Should the Phase 1 clinical trial yield positive results, the following step would involve running a Phase 2b safety and immunogenicity study, which might start as early as the second half of 2025, with an end of Phase 2b meeting with the FDA afterward and a potential Phase 3 clinical trial launching as early as 2026. As we told you previously, a partnership or other funding will be needed for these additional trials. We are still actively seeking partnerships and will share an update once one is available. I'd like to hand things over now to our Founder and Chief Science Officer, Dr. Sean Tucker, who will share recent updates on the preclinical work we've been doing for avian flu. Sean, go ahead.

Sean Tucker

executive
#4

Thanks, James. As most of you probably know, the H5 bird flu strain that's going around right now is leading to major outbreaks among wild birds, poultry, and dairy cattle throughout the United States. Up to now, the Centers for Disease Control and Prevention has documented 70 human cases of avian flu, and every one of them is thought to have come from exposure to infected poultry or cows. At present, there's no confirmed human-to-human transmission. When it comes to public health worries about avian flu spreading among people, the focus is on those who face infection risk because they've had contact with infected animals; even so, another worry is that the virus continuing to spread among animals could allow mutations to emerge that might make it better able to infect humans or could lead to transmission between people. Since this avian flu outbreak ranks as the biggest and most prolonged in U.S. history, interest is growing — along with the need — for a vaccine that is safe and effective and could shield those at risk of infection. Findings from recent preclinical research demonstrate that a novel avian flu influenza vaccine achieved 100% protection against death in a rigorous ferret clade 2.3.4.4b challenge model, whereas placebo-treated animals showed 0% survival. We anticipate reporting data from these studies in a peer-reviewed forum, which involves presenting the full results at a scientific or medical conference and ultimately getting the data published in a peer-reviewed journal. We think our avian influenza program holds promise as a partnership and business development opportunity, and we look forward to sharing additional data from the program later this year. In our view, the fairly short timeline for moving this new avian flu vaccine candidate into preclinical studies underscores how powerful our VAAST platform is at enabling quick development of novel vaccines capable of addressing the dynamic, evolving infectious disease landscape. Our modular, scalable, and standardized approach to vaccine development enables rapid creation of various vaccines targeting established targets, as well as new and emerging pathogens. Because of that, we believe we have a key role in innovating vaccines that are simpler to develop and deliver than traditional injected vaccines and mRNA vaccines. I'll now turn the call over to Phil Lee, our CFO, for a brief discussion of our financials. Phil?

Phillip Lee

executive
#5

Thanks, Sean. Today's press release contains a summary of the specifics behind our financial results for the first quarter of 2025. We brought in $20.9 million in revenue during the first quarter of 2025, which compares with $2.2 million in the first quarter of 2024. The BARDA contract granted in June 2024 accounted for most of our revenue in the first quarter of 2025. Most of the revenue in the first quarter of 2024 came from the BARDA contract granted in January 2024. Vaxart finished the first quarter holding $41.9 million in cash, cash equivalents, and investments. As Steve noted previously, over the last few weeks the company put additional measures in place to lower operating costs and better align its workforce with what its business requires. According to our present plan, Vaxart anticipates cash runway extending into the first quarter of 2026. In order to push our cash runway out even further, Vaxart will stay aggressive when it comes to seeking strategic partnerships and going after other non-dilutive funding options. As was announced in a press release today, I have delivered my notice of resignation from Vaxart as Chief Financial Officer. Choosing to leave the company at this important juncture was not something I took lightly, but I made this decision for personal reasons. I want to thank Steve, the board and the whole organization for giving me the chance to work at the leading oral vaccine biotechnology company. I will now hand the call back to Steve for closing remarks.

Steven Lo

executive
#6

Phil, thank you. The board and the entire company want you to know how much we appreciate all you've done for Vaxart, and we're wishing you the very best going forward. Before we open things up for your questions, I'd like to use this time to talk about our next annual shareholder meeting. It's happening virtually on Wednesday, May 21st, starting at 11:30 a.m. Eastern Time, which is 08:30 a.m. Pacific time. Specifically, I want to cover the reverse stock split that appears in proposal number two and explain how we arrived at this decision. Many of our shareholders, just like us, feel that today's stock price falls far short of what we believe our company is truly worth. To be clear, management team members and the board have experienced losses too, much like investors holding our stock, because of where our share price has fallen. All the same, there's a possibility NASDAQ will remove us from its listing. And even with everything we've tried, among them numerous wins that our team walked through previously, we still haven't managed to get back into compliance with the $1 minimum bid price rule that NASDAQ enforces. Before the late June cutoff, our view is that a reverse stock split represents the final option available. I want to use this moment to lay out the reasons we think approving proposal number two serves the best interests of Vaxart and of you, our shareholders. Our board and management would rather not pursue a reverse stock split, yet we see it as required for these reasons. To begin with, the main reason we are proposing this reverse split is to keep our listing on NASDAQ. Let me say again that avoiding a reverse stock split would be our preference. Still, at this point it is the strongest option we have to return to compliance and hold onto our NASDAQ listing. If NASDAQ were to delist us, that would probably hurt the worth of our company and the worth of your stock in a material way, because liquidity on the OTC markets is much thinner, and that could push the stock price lower. During last week's note to shareholders, I mentioned that assuming we get back into compliance with NASDAQ within the window they require, a reverse stock split is not something the board plans to pursue. Also, keeping our listing on NASDAQ could widen the appeal we have among investors. A lot of brokerage firms, along with investment funds, steer clear of shares trading at low prices, which turns investors away from businesses whose shares aren't on a major exchange. Most institutional investors would be put off by the drawbacks that come with trading on an exchange that isn't as well recognized. On top of that, we expect that being delisted might cause financial analysts to stop their research coverage. With that research coverage gone, market visibility would shrink and investor sentiment, as well as their grasp of the value we offer, could suffer as a result. Let me make one thing clear: when Vaxart does a reverse stock split, the effect hits every outstanding share of our common stock in the same way, and it won't water down anyone's stake. As we said earlier on this call, we continue to work aggressively toward securing business development partnerships and non-dilutive financing options, with the goal of reaching our upcoming clinical and regulatory milestones. If our shareholders give their approval, then before we actually put a reverse stock split into effect, the first thing we'll do is take stock of our situation to determine how probable it is that we can get back into compliance with NASDAQ. A number of things keep shifting, such as, though not limited to, where our programs stand and what our stock price is doing. Should compliance fail to happen by the June 30th deadline, a written notice from NASDAQ is anticipated, saying Vaxart's securities would face delisting. When that happens, Vaxart could appeal the delisting before a NASDAQ hearings panel and lay out its argument for staying listed. Even so, we can't guarantee NASDAQ will agree with that appeal. We keep assessing and using up every option available to us so a reverse split is avoided and our NASDAQ listing stays intact. We take pride in the major breakthroughs achieved, yet plenty of work remains that will demand ongoing investment. Vaxart has made great strides toward creating a novel oral pill vaccine capable of transforming how vaccination happens worldwide. The latest reversal of the HHS stop work order on our COVID trial brings real encouragement, made even stronger by HHS saying it believes novel vaccine technologies going past typical needle-based methods need to be developed. Getting to continued success for Vaxart depends on your backing. Messages have poured in from our devoted shareholder base, and I can say I've read them. Your enthusiasm and your frustration about our share price are feelings I share, yet reaching the finish line and carrying on our vital research work requires your support. Thank you all for spending time with us today. The call is now open for your questions.

Cheng Li

analyst
#7

Hello there. Hope you're having a good afternoon. I appreciate you fielding the questions, and congratulations on the momentum — wishing you the very best going forward. I might have a couple of questions for you, one regarding COVID-19 and another regarding norovirus. Regarding the COVID-19 program, I'm just wondering whether you can offer any color about what's holding up the beginning of patient dosing. I believe you said dosing should kick off during the second quarter, and I'd also like to know how quickly you believe you can get all 10,000 participants enrolled in that Phase 2b study. Then for the norovirus program, could you help us understand what to expect from the Phase 1 data and what would make you call that study positive? Thank you.

Steven Lo

executive
#8

Great. Hello, John; this is Steve. I really appreciate those questions. Regarding what you asked about COVID-19, I'll offer a couple of thoughts and then hand things over to James too. On norovirus, I believe both Sean and James are able to address that; so, when it comes to the gating factors, to begin with, we are clearly quite happy that the stop work order has been lifted. And right after that happened, we — honestly, the following day held a conference call, a Zoom meeting with BARDA. And as part of getting things restarted, there were simply certain items we had to get underway, such as screening of patients, and so on; so those represent the natural subsequent steps for the study. And after we manage to check off a number of those steps, we're hopeful that we'll receive the green light to begin dosing. I'll hand it to James in case he'd like to add a few more specifics about that.

James Cummings

executive
#9

Okay, thank you, Steve. Regarding how long the trial will take to enroll patients, I would put it at roughly 5 to 6 months. The reason I say roughly is that we are going to review how enrollment looks following screening across the initial several weeks and then modify our projections accordingly. I hope that addresses what you were asking.

Steven Lo

executive
#10

Alright. Moving on, Cheng, here's what we can address — you raised a question about norovirus, and more precisely, what would constitute a successful Phase 1? Sean, would you like to speak to that at a broad level? And after that, James, feel free to jump in.

Sean Tucker

executive
#11

From where we sit, I'd say doing well would mean the new constructs show a better trend than the old ones. We didn't — the study isn't large enough for us to seek statistical significance, but our expectation is that on key immunogenicity endpoints, the new constructs will perform slightly better.

James Cummings

executive
#12

I agree as well. My view is that our decision to proceed with that trial is grounded in certain preclinical findings that are quite compelling. Therefore, we are eager to receive those results — with top-line data expected at some point during this year.

Steven Lo

executive
#13

Yes, we're definitely — thank you, Sean. Yes, we're definitely happy that we managed to finish getting everyone enrolled as quickly as possible, allowing us to reach that important point.

Cheng Li

analyst
#14

Got it. I appreciate all the detail.

Mayank Mamtani

analyst
#15

Hello, good afternoon, everyone. Thank you for fielding our questions. All the best to Phil, and I'm eager to collaborate with Jarone. So, perhaps just to build on the COVID program, that particular BARDA communication you're engaged in before you begin dosing in the 10-K subject trial — has anything emerged from the sentinel cohort that sheds light on those talks? And also, could you perhaps share how you intend to address the sentinel cohort data later this year? After that, I'll pick up on your guidance.

Steven Lo

executive
#16

Wonderful. Sure, I'll have James provide a bit more specificity here. As I mentioned previously, these discussions have proven quite fruitful. I believe we fold in everything we gain from enrollment and so forth, plus the way we deliver comparator, along with our product, to the various sites. So that's definitely something we keep advancing. I'll hand things to James for the study's particulars.

James Cummings

executive
#17

Thank you, Steve. Now that the hold has been lifted and we're in the process of getting study sites up and running again — or started for the first time — and putting people through screening, that really amounts to the initial stage before anyone gets enrolled or dosed. We have 20 sites now active, and roughly 199 individuals have been screened or are going through screening at this moment. That effort follows a rising trajectory, and it will keep rising as additional sites come online and as we hold what I'd call a very solid stance when it comes to screening and enrollment.

Mayank Mamtani

analyst
#18

I apologize — what I was asking about concerned the sentinel cohort, those 400 subjects, since that information might prove useful in a number of ways, peer-appointed enrollment among them, James, so perhaps you could weigh in on it.

James Cummings

executive
#19

Certainly. What I would say is that our plan is to talk with our partners at bar about whether an interim analysis of some kind involving that group would benefit both sides equally. As far as the 12 months of safety follow-up goes, the trial is scheduled to wrap up by December of this year. We're blinded too. Since this is a double-blinded study, right now there's nothing more I'm able to share beyond that.

Mayank Mamtani

analyst
#20

Thanks. Now, regarding that DSMB assessment of the norovirus study that happened not long ago — could you say something about which things they examined? And could you also give your thoughts on what the recent Phase 1b paper showed, plus how the whole package is shaping up? If an end of Phase 2 meeting is what you're aiming for, my assumption is that data from the earlier-generation construct would matter too when talking with the regulators. Could you tie that all together — how you intend to handle it before this year wraps up? Appreciate you fielding these.

Steven Lo

executive
#21

Absolutely. James is able to share a few specifics on that, though as far as our dealings with the FDA go, I believe we've mentioned before, correct, that they consider the data in its entirety; therefore, everything gets folded in. That said, James, go ahead and offer any additional context.

James Cummings

executive
#22

Thanks, Steve. So, regarding our SMC — that's the Safety Monitoring Committee — for the Phase 1 trial, what we were examining, in general, was safety, to make sure we observe a clean safety profile with no areas of concern that would prevent us from proceeding with the protocol as designed and written. And the safety data was reviewed once the low-dose cohort finished, and then following some sentinel members of the higher dose cohort. Again, consistent with our entire platform, we see a safety profile that is very similar to placebo. For details in terms of the Phase 1, Sean, do you want to comment on your thoughts in terms of the immunologic outcomes there?

Sean Tucker

executive
#23

Absolutely. Once that challenge study wrapped up, we managed to pinpoint a pair of key immune parameters that we considered significant. The first involves essentially examining functional antibodies in sera (ph), along with fecal IgA responses. Both of these parameters are going to be measured by us in the new study, and drawing on our preclinical work, our hope is that the new constructs will show a better trend than the old construct.

Mayank Mamtani

analyst
#24

Thanks.

Liang Cheng

analyst
#25

Hello, I'm Liang Cheng, calling in for Roger. We appreciate you fielding our questions, and congratulations on the advancement. So we have a few things to ask. To start, regarding the COVID program. I'm curious about the stop order and how it affects the timeline you expect for finishing a study — could you also briefly remind us where the study is being run and what your thinking is on seasonality in that location? Then about the norovirus program, since we understand Phase 2 will likely hinge on a possible partnership. Are there any active discussions taking place at this moment? Thank you.

Steven Lo

executive
#26

Hello, Liang. I appreciate the question. I'll briefly discuss the stop work order, then James can share his view, and after that we'll address the partnership topic. First, we felt quite good that the stop work order we got on February 21st covered 90 days. And the fact that it got lifted after 60, 62 days definitely beat what we expected, since we assumed it would run the entire 90 days. Also, to your point, there were 60 days during which nothing could be done, which caused a small impact, and James can speak to the fact that, as he said before, we were working to get the sites up and running again as quickly as we could. But James, would you like to address anything regarding enrollment and projections?

James Cummings

executive
#27

Alright, then. So within the scope of that study, the halt — that stop work order — did have an effect on the 10,000 person group in this trial, yet the 400-person sentinel portion carried on. Those participants had already received their doses; we were already monitoring them for safety, and that effort is ongoing. That sentinel group of 400, as I noted earlier, ought to wrap up clinical follow-up in December of this year, and following unblinding analysis of samples and locking of the data, you'd be looking at a three- to six-month timeframe for some of those data. Regarding the 10,000 person group, once dosing gets underway, my projection — and this is a prediction — is roughly a six month enrollment window; we'll find out more as screening proceeds and as we start enrolling and dosing people, we'll understand better how long that stretch will be. Starting when the final participant is enrolled, a 12-month follow-up period applies, during which we examine safety and immunogenicity, and efficacy as well, both from a symptomatic angle — someone who has symptoms and comes in to be screened to determine whether they truly have the SARS-CoV-2 virus and COVID-19 infection — and through asymptomatic surveillance, which will happen across the 12 months after they've gotten either our investigational vaccine construct or the approved vaccine. And I find that quite compelling given how COVID-19, the SARS-CoV-2 virus, behaves, since it mutates over time. So we'll be examining not only protective efficacy, but also which types of viruses may have mutated in ways that might not be as favorable for a direct IgG response — though we believe our mucosal response could potentially offer an advantage.

Steven Lo

executive
#28

And, Liang, it's Steve here. I'll take your question about the norovirus partnership talks. First off, we view norovirus as a really significant opportunity. There's an unmet need in this area, and we know lots of companies are also going after norovirus. So I'd say it's a promising market, and on top of that, plenty of companies out there lack a norovirus vaccine in their portfolio. And certainly, if you're a big global multinational, that's something that could be attractive. We're in discussions with a wide and varied set of companies. As I mentioned, those include some of the big multinationals, and some mid-sized ones too. These companies are global as well as some regional players located in the United States, but also beyond the United States; and I think everybody, just like us, is waiting for the top line results, which we've told everyone to expect at mid-year of this year; so I think once those results come in, it's our expectation that those discussions will speed up. But from where we sit, we're happy that there's interest in norovirus. It definitely backs up our thesis that, you know, this is a terrific market opportunity. And honestly, we're the only ones I know of that have an oral vaccine in development.

Liang Cheng

analyst
#29

That's really useful, I appreciate the extra detail.

Ed Berg

executive
#30

Thanks, operator. I'd like to express gratitude to those who hold shares in our company. A substantial set of questions came in written form from them, touching on each of our programs, our science, financial topics, and the reverse stock split we've proposed. So we'll take those questions in that sequence. Steve, the initial one concerns our COVID program. Given that yours is the sole company so far to have a stop work order removed for Project NextGen, could you say more about what you've discussed with BARDA and HHS?

Steven Lo

executive
#31

Okay, thank you. To begin with, like I mentioned before, we feel appreciative and glad that the stop work order has been removed; I believe that came about because of several constructive discussions we held with BARDA and HHS during that period; they definitely assessed our program based on its merits and the science behind it. On our end, those discussions were constructive, and I'm certain everyone will understand that they must remain confidential too; we've been told that these talks are, I think, at a stage where sharing isn't possible since we want to honor our contract with BARDA and our relationship with them. Still, we do think they were constructive, and that might be one reason the stop work order got lifted.

Ed Berg

executive
#32

Appreciate it. I should mention as well that our knowledge is limited to our own program and whatever has been made public. Regarding anything beyond that, we simply have no details, just so that's clear for everybody. Now, a shareholder has raised something on the norovirus side. With the norovirus trial, you've got a low dose and a high dose being tested, and you've referenced responses that vary by dose in earlier trial data. Given that, what drove the choice to go with the lower dose in the Phase I clinical trial? James, could you take that one?

James Cummings

executive
#33

Okay, thank you, Ed. The dosage that we administered in the earlier Phase 2 study was 1E11 (ph) for each strain. Keep in mind that this is a bivalent vaccine, meaning it contains two strains. That amount was selected based on safety and immunogenicity results from prior trials. In this trial, our plan is to evaluate the 1E11 dose of a legacy vaccine against both a lower dose, 1E10, and a higher dose, 1E11, per strain of our second generation norovirus candidate; doing so will let us pick the right dose going forward. Dose ranging studies are truly the standard of care for any novel vaccine construct; therefore, we are running this trial to identify the optimal dose that gives us the greatest likelihood of boosting efficacy while maintaining comparable safety.

Ed Berg

executive
#34

Appreciate that, James. There's something we'd like to ask Sean regarding bird flu. The early data on avian flu look quite encouraging. What's the timeline for getting that candidate into the clinic?

Sean Tucker

executive
#35

At this moment, we remain in the preclinical stage of our research. There are additional developments on the horizon for us. Naturally, we believe our candidates are capable of being produced extremely fast, and at present we are preparing to make certain drug products intended for clinical application. Clearly, once the results are ready, we will release them as soon as they become available.

Ed Berg

executive
#36

Thanks. I've got a science-related question for Sean. The Department of Health and Human Services just allocated $500 million toward advancing universal flu vaccines, ones that might guard against every strain of the virus. How do you view the outcomes of that vaccine compared with Vaxart's? Also, would you say Vaxart's vaccine's cross reactivity matches theirs?

Sean Tucker

executive
#37

Sure, we're definitely glad to see HHS putting funds toward new ways of doing vaccines and technology, and that includes what we're working on. We genuinely think that our distinctive mechanism of action, plus how convenient it is, could really distinguish us from every other vaccine technology that exists. On top of that, we think being able to produce cross reactive IGA might prove useful both for flu and for additional indications.

Ed Berg

executive
#38

Appreciate it. Now we're shifting away from our programs and over to the financial side of things; turning to Steve — my mistake, to Phil, you've gotten money from the government, and it's possible that additional funds could come your way through this award. That cash can't be put toward running the company's operations.

Phillip Lee

executive
#39

I guess the most effective approach here is to begin with a handful of the important monetary details tied to this award. To start with, it gives us money available amounting to as much as $460.7 million at present. What matters is that, out of that $460.7 million, $240.1 million can be drawn on right now for payments. Then, per what we shared in the press release issued today, the business has in fact already collected $85.6 million in cash payments up to March 31st, 2025. So how does that affect Vaxart? The thing is, most of the money Vaxart gets is in fact spent paying vendors who carry out the COVID-19 Phase 2b trial. A share of this award handles part of our overhead, plus a fee that Vaxart earns for running the trial. That share, then, does get used by us to assist with covering the company's operations, and it is in fact factored into our present cash runway guidance pointing to cash lasting into the first quarter of 2026. I also want to repeat that, just as with any other government contract, this award does not fund all of the company's operations.

Ed Berg

executive
#40

Appreciate that, Phil. I've got one more question on the financial side for you. Was any capital actually raised through the ATM you established back in March?

Phillip Lee

executive
#41

For anyone listening in who might not know this, back in March of this year we submitted a filing for what's called an at the market offering, or ATM for short. Having that ATM filed gives Vaxart the ability — though not any requirement — to bring in as much as $50 million in our particular situation by issuing shares on the open market. As was said before, we share the view held by many of you that our value is being underestimated. In fact, selling stock at today's price isn't something we wish to do. So after establishing the ATM in March, we haven't sold a single share through today's call. To put it briefly, essentially no equity financings, and no dilution tied to financings, have taken place since our prior earnings report.

Ed Berg

executive
#42

Appreciate that, Phil. Now we’re going to turn to some questions regarding the reverse stock split. These are directed at Steve. To start, what factors were involved in choosing not to change the authorized share count? Is it possible to amend that before the annual meeting?

Steven Lo

executive
#43

Okay, so the first thing I'd like to do is recognize and say thanks to everyone who has submitted questions, to all of our shareholders, and in particular to our retail shareholders, who care deeply about this topic. We get a large number of questions on that front, and we truly want to acknowledge that, and to make clear that we hear your worries. Where we currently stand in this process, we did explore ways we might modify the proposal, simply because — regrettably, the shareholder meeting takes place next week, so amending the proposal at this point comes a bit too late; even so, your concerns are being factored in. We are examining and assessing the best way to handle this before the annual meeting arrives. We recognize how much it matters to you, and on our end too, as Phil said, it is not our aim to cause a great deal of — to bring about substantial dilution of our stock. So we'll be examining this, and we will definitely provide an update as soon as we're able.

Ed Berg

executive
#44

Appreciate that, Steve. Let me move on to something along similar lines. Do you have any plans to adjust the reverse stock split down to a more sensible figure? If it does get approved, what factors play a role in setting the split ratio?

James Cummings

executive
#45

Right, so at the point when we began this effort — and I should also bring everyone up to speed that, regarding our NASDAQ filing to remain compliant, we're now in month seven through twelve of that process, and one aspect of what's needed to get back into compliance, based on our talks with NASDAQ, is that we must present a strategy for climbing above a dollar, and that in fact involves having to consider a reverse stock split. That, then, was step one. Step two involved examining a band of ratios that might be reasonable; and we had — the board was given a broad range so flexibility would be maximized; having said that, right now we aren't focused on carrying out a reverse split at a 1-to-50 ratio. As I noted in a recent letter to stockholders, should it be approved, the board's genuine plan is to pick a reverse stock split ratio large enough that we resolve the NASDAQ shortfall. Naturally, our preference is to avoid needing that by reaching our key milestones and continuing to execute on our strategies. If, however, we find ourselves in that position, then we aim to choose only a ratio modest enough to bring us into NASDAQ compliance.

Ed Berg

executive
#46

Appreciate that, Steve. One more thing I'd like to ask — in the event that compliance isn't won back before the deadline, are you getting ready to file an appeal with NASDAQ asking for more time, particularly given that the program was recently paused?

Steven Lo

executive
#47

Right. So, like I mentioned before, once NASDAQ granted us that second extension of six months, the condition was that our company needed a strategy in place to carry out a reverse stock split. That's why it's built into this process, and that's the reason we're bringing the vote to our shareholders. NASDAQ has told us that they won't discuss any extension until the June 30th cutoff has passed. That's exactly why we're looking for that flexibility. Of course, what we're doing is requesting that shareholders approve proposal number two, and our plan is to only put it to use if necessary.

Ed Berg

executive
#48

Appreciate it. And I figure this is a good place to wrap up with this one, since I know a number of our shareholders have genuinely been curious about it, and that is: why not simply take the company off NASDAQ and have it trade over the counter?

Steven Lo

executive
#49

Appreciate that, and yeah, we hear that point often, and we've dug into it. We examined the matter too, and based on what we can tell, getting removed from NASDAQ would deal a substantially harmful blow to what our shares are worth. Once a company's shares trade on an OTC market, liquidity is considerably thinner, and that too might drag the stock price down. As you're probably aware, plenty of brokerage firms and investment funds truly avoid stocks at lower prices along with companies lacking a listing on a major exchange, and that might likewise turn away other prospective investors. The constraints attached to trading on a less prominent exchange might additionally scare off institutional investors. So we genuinely have no wish to be listed on such an exchange, since it might additionally cause a decline in research coverage from the analysts who cover us, who have been extremely supportive and with whom we enjoy a solid relationship; so to put it briefly, we firmly hold that remaining on NASDAQ serves the best interests of the company and its shareholders.

Ed Berg

executive
#50

Appreciate that, Steve. That wraps up all the questions we have right now. Operator, would you go ahead and bring this to a close?

Operator

operator
#51

Yes, thanks. That brings today's call to a close. At this point you're free to hang up, and we appreciate your joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.